Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 4.13
AXON's Cash-to-Debt is ranked lower than
64% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. AXON: 4.13 )
Ranked among companies with meaningful Cash-to-Debt only.
AXON' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.13  Med: N/A Max: No Debt
Current: 4.13
Altman Z-Score: 12.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -90.09
AXON's ROE % is ranked lower than
75% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. AXON: -90.09 )
Ranked among companies with meaningful ROE % only.
AXON' s ROE % Range Over the Past 10 Years
Min: -102.82  Med: -97.62 Max: -90.09
Current: -90.09
-102.82
-90.09
ROA % -75.22
AXON's ROA % is ranked lower than
78% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. AXON: -75.22 )
Ranked among companies with meaningful ROA % only.
AXON' s ROA % Range Over the Past 10 Years
Min: -93.89  Med: -82.78 Max: -71.66
Current: -75.22
-93.89
-71.66
ROC (Joel Greenblatt) % -150974.96
AXON's ROC (Joel Greenblatt) % is ranked lower than
98% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. AXON: -150974.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AXON' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -271759.18  Med: -214177.43 Max: -150974.96
Current: -150974.96
-271759.18
-150974.96
GuruFocus has detected 2 Warning Signs with Axovant Sciences Ltd $AXON.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AXON's 30-Y Financials

Financials (Next Earnings Date: 2017-08-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

AXON Guru Trades in Q2 2016

PRIMECAP Management 740,802 sh (-2.65%)
» More
Q3 2016

AXON Guru Trades in Q3 2016

Steven Cohen 645,300 sh (New)
Jim Simons 69,800 sh (New)
PRIMECAP Management 740,802 sh (unchged)
» More
Q4 2016

AXON Guru Trades in Q4 2016

Jim Simons Sold Out
PRIMECAP Management 719,502 sh (-2.88%)
Steven Cohen 11,500 sh (-98.22%)
» More
Q1 2017

AXON Guru Trades in Q1 2017

Steven Cohen 209,100 sh (+1718.26%)
PRIMECAP Management 2,878,930 sh (+300.13%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:AXON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:LSE:ABC, LSE:BTG, LSE:GNS, XPAR:STAGR, NYSE:MYOV, NAS:ADAP, LSE:CIR, LSE:OXB, LSE:MPH, LSE:HZD, LSE:ARIX, LSE:DDDD, LSE:TILS, LSE:OBD, LSE:VRP, LSE:ABZA, LSE:VER, LSE:TRX, LSE:BVXP, LSE:IMM » details
Traded in other countries:3AS.Germany,
Headquarter Location:UK
Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to address multiple forms of dementia and related neurological disorders.

Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Its drug candidate includes RVT-101. It is developing a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia. RVT-101's direct competitor is idalopirdine (Lu AE58054), a 5-HT6 receptor antagonist being developed by Lundbeck that is currently in Phase 3. In the United States, pharmaceutical products are subject to extensive regulation by the FDA.

Ratios

vs
industry
vs
history
PB Ratio 17.12
AXON's PB Ratio is ranked lower than
92% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. AXON: 17.12 )
Ranked among companies with meaningful PB Ratio only.
AXON' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 20.64
Current: 17.12
0
20.64
EV-to-EBIT -11.93
AXON's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. AXON: -11.93 )
Ranked among companies with meaningful EV-to-EBIT only.
AXON' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.66  Med: 0 Max: 0
Current: -11.93
-15.66
0
EV-to-EBITDA -11.94
AXON's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AXON: -11.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
AXON' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.66  Med: 0 Max: 0
Current: -11.94
-15.66
0
Current Ratio 4.75
AXON's Current Ratio is ranked higher than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AXON: 4.75 )
Ranked among companies with meaningful Current Ratio only.
AXON' s Current Ratio Range Over the Past 10 Years
Min: 0.29  Med: 4.75 Max: 17.9
Current: 4.75
0.29
17.9
Quick Ratio 4.75
AXON's Quick Ratio is ranked higher than
56% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. AXON: 4.75 )
Ranked among companies with meaningful Quick Ratio only.
AXON' s Quick Ratio Range Over the Past 10 Years
Min: 0.29  Med: 4.75 Max: 17.9
Current: 4.75
0.29
17.9

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 18.57
AXON's Price-to-Net-Cash is ranked lower than
77% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. AXON: 18.57 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AXON' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.37  Med: 8.63 Max: 21.41
Current: 18.57
4.37
21.41
Price-to-Net-Current-Asset-Value 17.51
AXON's Price-to-Net-Current-Asset-Value is ranked lower than
81% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. AXON: 17.51 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AXON' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.27  Med: 8.21 Max: 20.19
Current: 17.51
4.27
20.19
Price-to-Tangible-Book 17.10
AXON's Price-to-Tangible-Book is ranked lower than
87% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. AXON: 17.10 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AXON' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.27  Med: 8.07 Max: 19.71
Current: 17.1
4.27
19.71
Earnings Yield (Greenblatt) % -8.41
AXON's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. AXON: -8.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AXON' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2519.8  Med: 0 Max: 0
Current: -8.41
-2519.8
0

More Statistics

EPS (TTM) $ -1.82
Short Percentage of Float15.81%
52-Week Range $11.01 - 26.49
Shares Outstanding (Mil)107.39

Analyst Estimate

Mar18 Mar19 Mar20
Revenue (Mil $) 152 350
EPS ($) -2.44 -2.03 -0.08
EPS without NRI ($) -2.44 -2.03 -0.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NYSE:AXON

Headlines

Articles On GuruFocus.com
New Preclinical Data for Intepirdine Suggests Potential Neuroprotective Properties Jul 19 2017 
Dermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman Jul 10 2017 
Axovant to Present Key Intepirdine and Nelotanserin Data at Alzheimer's Association International Co Jul 10 2017 
FDA Grants Fast Track Designation to Axovant's Nelotanserin for Visual Hallucinations in Dementia wi Jun 19 2017 
Axovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates Jun 13 2017 
Axovant Announces Changes to Board of Directors Jun 06 2017 
Axovant Strengthens Executive Team with Key Management Appointments Jun 06 2017 
Axovant Sciences to Present at Upcoming Investor Conferences May 31 2017 
Axovant Sciences Ltd. Announces Closing of Public Offering and Exercise in Full of the Underwriters' Apr 17 2017 
Axovant Sciences Ltd. Announces Pricing of $125M Public Offering of Common Shares Apr 11 2017 

More From Other Websites
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Jul 18 2017
3 Small Biotech Stocks Being Run by Proven Winners Jul 17 2017
Dermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman Jul 10 2017
Axovant to Present Key Intepirdine and Nelotanserin Data at Alzheimer's Association International... Jul 10 2017
Earnings Review and Free Research Report: Axovant Sciences Reported Lower than Expected Earnings Jun 29 2017
Is This the Next Home-Run Biotech Stock? Jun 28 2017
Featured Company News - Juno Therapeutics Shared Updated Data for TRANSCEND NHL 001 Clinical Trial... Jun 20 2017
FDA Grants Fast Track Designation to Axovant's Nelotanserin for Visual Hallucinations in Dementia... Jun 19 2017
Rigorous Trial Design, Nice Risk/Reward Keep Analyst Anxious For Avoxant's Phase 3 MINDSET Data Jun 14 2017
Axovant reports 4Q loss Jun 13 2017
Axovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates Jun 13 2017
Axovant Strengthens Executive Team with Key Management Appointments Jun 06 2017
Axovant Announces Changes to Board of Directors Jun 06 2017
Axovant Sciences to Present at Upcoming Investor Conferences May 31 2017
Axovant: A New CEO Doesn't Change Anything Apr 18 2017
Axovant Sciences Ltd. Announces Closing of Public Offering and Exercise in Full of the Underwriters'... Apr 17 2017
Shark Bites: You Don't Want to Play the Gambler Today Apr 13 2017
Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2% Apr 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}